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ABSTRACT
The human genome comprises some 
20,000 genes, or 3 billion base pairs. Vari-
ation in this genetic sequence is common- 
and some of these variants affect gene 
function or the protein transcribed from 
it. Human characteristics are determined 
by the interaction of the genome with en-
vironmental challenges- and differences 
between us thus result from variation in 
those challenges and in the genome itself. 
This is true of human susceptibility to dis-
ease, and survival from it. Genetic varia-
tion influences human behaviours which 
may predispose to health or disease; the 
risk of contracting an infectious disease, 
or of suffering diseases such as cancer or 
myocardial infarction; the development of 
complications; the response to any treat-
ment administered; and thus the outcome 
of the disease state. Genetic studies can 
help shed light on the mechanisms which 
underpin disease processes, whilst perhaps 
suggesting ways in which treatment might 
be ‘personalised’, and novel therapeutic 
targets for drug development. 
More sophisticated approaches to such en-
deavours are required, given the failure to 
identify the bulk of gene variants of influ-
ence using conventional strategies.
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The human genome comprises some 
20,000 genes, themselves composed of 3 
billion pairs of bases. It is this shared and 
common inheritance which defines our 
species- which makes us all human. How-
ever, significant variation occurs within 
this genome. There are some 38 million 
sites of common variation, of which 15 
million sites exhibit a variant in >1% of 
cases. Overall then, whilst any two humans 
are genetically 99.9% similar, any individ-
ual is likely to differ from the human con-
sensus genome at about 3 million sites. (1) 
Such variation can take many forms- and 
any which occurs at a frequency of >1% is 
termed a ‘polymorphism’. At its simplest, a 
single ‘letter’ in the genetic sequence may 
be changed. If such a variation occurs at a 
frequency of >1%, then it is referred to as a 
single nucleotide polymorphism- or ‘SNP’. 
Short Tandem Repeats (STRs) are 1-5 base 
pair (bp) repetitive sequences, and ‘Vari-
able Number Tandem Repeats’ (VNTRs) 
are 5-64bp long repeats which can extend 
over thousands of base pairs. ‘Copy Num-
ber Variants’ (CNVs) occur when whole 
blocks of a gene are deleted, duplicated or 
inverted. At the other end of the spectrum, 
entire arms of chromosomes can be invert-
ed, or chromosomes duplicated. (2)
Such variants may have no biological ef-
fect at all. However, others can affect hu-
man form and function. Most SNPs are 
‘silent’ being sited outside coding regions 
and having no effect on gene expression. 
However, they may also be found in areas 
of the gene which effect its expression, or 
may alter its splicing. Those found in the 
coding region may affect the amino-acid 
sequence for which the gene encodes (they 
are ‘non-synonymous’) by either altering 
an amino acid (a ‘missense’ variant) or by 
cause a premature ‘stop’ in translation (a 
‘nonsense’ variant). They may also affect 
splicing. 
Whilst some diseases are entirely due to 
the presence of a rare gene variant, this is 
usually not the case: most human charac-
teristics (or phenotypes) result from the 
interaction of an individual’s genome with 
the environment to which it is exposed. 
Inter-individual differences in human 
phenotype thus result from differences 
in environmental exposures interacting 
with differences in genome sequence. In 
general, upwards of 25% of the variation 
in any human trait is due to genetic varia-
tion- and it can be much more. Some 45% 
of the variation in human height can thus 
be accounted for by genetic variation. (3)
Human susceptibility to disease is thus 
profoundly influenced by the genetic vari-
ants we inherit, as is the outcome from 
such disease states. Analysis of data relat-
ing to nearly 10,000 births from two vil-
lages between 1650 and 1927 shows lon-
gevity to be highly heritable (4). Indeed, 
some 25% of the variation in human life 
expectancy being accounted for by genetic 
variation (5). These influences are stronger 
the older one becomes (perhaps due to a 
restriction in environmental challenges). 
Few if any loci have been identified which 
are proven to exert strong effect, although 
the sex chromosomes themselves appear to 
influence human longevity, with late sur-
vival (life expectancy on reaching the age 
of 50 years) in studies of historical datasets 
from France suggesting greater heritability 
for daughters than sons. (6)
Such influences on survival are not merely 
due to impacts on factors which all clini-
cians would identify- the risk of myocar-
dial infarction, for instance. Sorensen and 
colleagues followed 960 families with chil-
dren born from 1924-26 who were then 
adopted by unrelated individuals. Risk of 
death aged 16-58 was determined. In keep-
ing with the heritability of longevity, the 
relative risk of death was 1.7 if a biological 
parent had died before the age of 50 years. 
Relative risk of the same cause of death 
was 1.19 for cancer, 4.5 for cardiovascular 
and cerebrovascular disease and 5.8 where 
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death was due to infection. (7)
Genetic variation can interact at every 
level in determining survival. Some 46% 
of the variation in female participation in 
recreational exercise is determined by ge-
netic variation, with perhaps as much as 
68% of that in males being accounted for 
in this way. (8) A Genome-Wide study of 
leisure-time exercise in 978 European-an-
cestry American and 1644 unrelated Dutch 
adults revealed 37 SNPs associated with 
exercise participation. (9) Such a genetic 
influence might improve survival (through 
reduced cardiovascular risk) or increase it, 
if such participation related to engagement 
in ‘risky’ sports or other behaviours. Such a 
propensity to take risk may in itself also be 
genetically influenced. Between 30% and 
60% of the variation in susceptibility to ad-
dictive diseases has a genetic origin- with 
some specific variants being associated 
with addition to specific drugs (reviewed 
in (10)). Some of this appears attribut-
able to genetic variants which are associ-
ated with novelty-seeking, thrill-seeking or 
risk-taking, as well as to addiction to any 
activity found pleasurable. Likewise, the 
‘stress response’ to challenging situations 
may also be partly genetically-determined. 
(10)
Genetic variation can influence the re-
sponse to drugs in a number of ways- 
whether through altered pharmacoki-
netics or pharmacodynamics, or altered 
cellular activity (e.g. those with two defec-
tive CYP2D6 alleles who are administered 
tamoxifen for breast cancer have much 
lower levels of the active metabolite en-
doxifen, and thus respond less well, whilst 
patients those carrying two rare CYP2D6 
alleles can’t break down codeine to yield 
morphine). Indeed, some 20 gene loci af-
fecting 80 or more medications have been 
identified to date which might find clinical 
application in medical practice. (11)
Other genetic variants can influence the 
chance of contracting an infectious disease 
once exposed. Indeed, by way of exemplar, 
genetic variation strongly influences sus-
ceptibility to HIV-1 infection (12). How-
ever, a genome-wide association studies 
(GWAS) of patients with haemophilia A 
who received potentially-contaminated in-
fusions of human factor VIII between 197 
and 1984 (before viral inactivation was in-
troduced) failed to identify associated ge-
netic variants, however. (13) Others have 
similarly failed- and such failure is not un-
usual in other scenarios. Thus, whilst some 
45% of variation in human height is due to 
genetic factors, only 5% of this variation 
can currently be accounted for by known 
genetic variants(3). This is likely because 
many genes each exert a small influence, 
because gene variants interact in complex 
and non-additive ways to influence risk, 
and because genome-wide studies (usu-
ally across >1 million genetic sites) require 
a statistical stringency which means that 
many variants of influence do not reach 
statistical significance in association.
It might thus appear impossible to iden-
tify genetic variants which might influence 
outcome from complex disease states such 
as those identified on the Intensive Care 
Unit (ICU). However, such influences are 
recognised- and some loci identified. Thus, 
angiotensin-1 converting enzyme (ACE) 
plays a pivotal role in the human circulat-
ing and tissue rennin-angiotensin systems, 
yielding biologically-active angiotensin II 
from (inert) angiotensin I, whilst degrad-
ing kinins. A common genetic variant ex-
ists in this gene, the absence (deletion, D 
allele) rather than the presence (Insertion, 
I allele) of a 287 base pair sequence being 
associated with higher circulating (14) and 
tissue (15, 16) ACE activity. ACE appears 
to play a role in the regulation of tissue 
metabolic and inflammatory responses, 
as well as to the response to hypoxia- the 
I-allele being associated with improved 
performance in the hypoxic environment 
associated with high altitude (reviewed in 
(17)). Perhaps because of such effects, the 
D-allele has been associated with impaired 
outcome from meningococcal infection in 
children (18). Inheritance of two D-alleles 
is associated with an up to 5-fold increased 
mortality from acute respiratory distress 
syndrome in adults when compared to 
those with two ‘I’-alleles. (19-21). Such 
risk may extend to risk of developing no-
socomial pneumonia. (22) Meanwhile, the 
large-scale and multinational GenoSept 
study has identified a common variation 
in the FER gene which is associated with 
survival (or mortality) from sepsis in the 
context of pneumonia. The presence of 
each C (rather than T) base being associ-
ated with reduced mortality when adjusted 
for age, with mortality being 9.5%, 15.2% 
and 25.3% for those of CC, CT and TT 
genotype respectively (23)
In summary, then, genetic variation 
strongly influences human behaviours 
which may predispose to health or disease; 
the risk of contracting an infectious dis-
ease, or of suffering diseases such as cancer 
or myocardial infarction; the development 
of complications; the response to any treat-
ment administered; and thus the outcome 
of the disease state. Genetic studies can 
help shed light on the mechanisms which 
underpin disease processes, whilst perhaps 
suggesting ways in which treatment might 
be ‘personalised’, and novel therapeutic 
targets for drug development. However, 
more sophisticated approaches to such en-
deavours are required, given the failure to 
identify the bulk of gene variants of influ-
ence using conventional strategies.
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